🟢 Eli Lilly is trading 5.34% up today after strong Q2 results and higher 2026 guidance

Eli Lilly is trading 5.34% up now at $1291.24, as investors continue rewarding strong second-quarter results and a higher 2026 revenue outlook.

• Second-quarter revenue rose 48% to $23.0 billion, driven primarily by Mounjaro and Zepbound volume.
• Full-year revenue guidance increased to $85.0 billion–$87.0 billion.
• The move aligns with a broader healthcare-sector rally, with XLV up 3.23%.